

AACR Special Conference
Ovarian Cancer
October 5-7, 2023 | Boston, MA

AACR
American Association for Cancer Research

Current as of September 26, 2023

Short Talks Selected from Proffered Abstracts

PR-01 **Stable subclones and acquired genomic events present after treatment of HGSC**. Jaana Oikkonen. University of Helsinki, Helsinki, Finland.

PR-02 **Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer**. Paul Workman. The Institute of Cancer Research, London, London, United Kingdom.

PR-03 **Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive**. Liisa Kauppi. University of Helsinki, Helsinki, Finland.

PR-04 **The evolution of ovarian high grade serous carcinoma from STIC lesions**. Zhao Cheng. Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.

PR-05 **ZNFX1 is a Master Regulator for Epigenetic Reprograming of Mitochondrial Inflammasome Signaling and Pathogen Mimicry in Cancer Cells**. Lora Stojanovic. Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, United States.

PR-06 **A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer**. Devivasha Bordoloi. The Wistar Institute, Philadelphia, United States.

PR-07 **Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer**. Anniina Färkkilä. University of Helsinki, Helsinki, Finland.

PR-08 **Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells**. Amrita Salvi. University of Illinois, Chicago, Chicago, United States.

PR-09 **Reconstructing the metastatic tumour microenvironment of high grade serous ovarian cancer using human multicellular in vitro models**. Beatrice Malacrida. Queen Mary University of London, London, United Kingdom.

PR-10 **Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment**. Benjamin Bitler. The University of Colorado, Denver, United States.

PR-11 **Role of cancer associated fibroblasts in ovarian cancer relapse**. Argha Ghosh. Indiana University School of Medicine - Bloomington, Bloomington, United States.



PR-12 **Proteogenomic Analysis of Enriched Tumor Epithelium Identifies Prognostic Signatures and an Increased Dependency of Homologous Recombination Proficient Cells on BMI1 in High Grade Serous Ovarian Cancer**. Thomas Conrads. Inova Health System, Falls Church, United States.



AACR Special Conference
Ovarian Cancer
October 5-7, 2023 | Boston, MA

AACR American Association for Cancer Research

Poster Session A (To be presented on October 5 from 7:30-10:00 p.m. ET)

Patient Advocacy

A001 **Financial Toxicity and Social Needs in Patients with Ovarian Cancer: A Multi-Practice Survey**. Anna Jo Smith. University of Pennsylvania, Philadelphia, PA, United States.

A002 **Collaboration Between the Physician/Researcher and Patient/Survivor is KEY**. Deborah Binder. Patient Advocate, Edmonds, WA, United States.

Epigenetics and Epitranscriptomics

A003 **Characterizing DNA methylation patterns driving chemotherapy resistance in ovarian high-grade serous carcinoma**. Alexandra Lahtinen. University of Helsinki, Helsinki, Finland.

A004 **Patterns of lncRNA-regulated gene expression in high-grade serous ovarian carcinomas**. Brett Reid. Moffitt Cancer Center, Tampa, FL, United States.

A005 **Alanine metabolism is a ARID1A-dependent vulnerability in clear cell ovarian carcinoma**. Hao Nie. MD Anderson Cancer Center, Houston, TX, United States.

A006 **Loss of XIST induces tumor metabolism reprogramming in ovarian cancer.** Ikrame Naciri. University of California, Irvine, Irvine, CA, United States.

A007 **DNA methylation analysis comparing high-grade serous ovarian cancer to the normal ovary with adjustment for cell type variation identifies tumor-specific methylation alterations**. Irma Vlasac. Geisel School of Medicine, Lebanon, NH, United States.

A008 **Characterizing the role of somatic and constitutional methylation in ovarian cancer**. Isabel Rodriguez. University of Washington, Seattle, WA, United States.

Drug Discovery, Development, and Novel Pathways

A009 **A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer**. Devivasha Bordoloi. The Wistar Institute, Philadelphia, PA, United States.

A011 **An implantable microdevice to interrogate responses to therapy in ovarian cancer**. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

A012 **Dual-selective inhibitors of PKMYT1 and WEE1 for improved potency and therapeutic profile**. Evan Chiswick. Psivant Therapeutics, Boston, MA, United States.

A013 **Auranofin induces lethality driven by reactive oxygen species in high-grade serous ovarian cancer cells**. Farah Abdalbari. McGill University, Montreal, QC, Cananda.



A014 **A valid second line therapy for high grade serous ovarian cancer**. Flavio Rizzolio. Ca' Foscari University of Venice, Venezia, Italy.

A015 **Glutaminase inhibitor induces Chk1-inhibitor induced replication stress and synergisticaly kills chemo-resistant and GLS ovarian cancer cells**. Ganesh Acharya. Texas Tech University Health Sciences Center, Lubbock, TX, United States.

A016 **Organotypic High-throughput Screening Identifies the Combinatorial Treatment of Navitoclax and YM155 that Target Chemoresistant Ovarian Cancer Cells.** Hilary Kenny. University of Chicago, Chicago, IL, United States.

A017 **An Analysis of 13 Independently Performed Assays to Measure Homologous Recombination Deficiency Using 90 Freshly Extracted High Grade Serous Ovarian Tumors: Findings from the Friends of Cancer Research HRD Harmonization Project**. Hillary Stires. Friends of Cancer Research, Washington, DC, United States.

A018 **CASC4/GOLM2 drives high grade serous ovarian cancer anoikis resistance through recycling of EGFR**. Jaidev Bapat. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A019 **Development of adaptive anoikis resistance promotes ovarian cancer metastasis that can be prevented by CDK8/19 Mediator kinase inhibition**. Resha Rajkarnikar. University of Alabama, Birmingham, AL, United States.

A020 **NAD+ Boosting through NRH supplementation enhances treatment efficacy in EOC**. Kevin Lee. USA Health Mitchell Cancer Institute, Mobile, AL, United States.

A021 **The beta-arrestin1/endothelin axis bolsters a CAF-dependent invadosome activity and ovarian cancer metastatic potential.** Laura Rosanò. Instiute of Biology and Molecular Pathology (IBPM)-CNR, Rome, Italy.

A022 **ZNFX1 is a Master Regulator for Epigenetic Reprograming of Mitochondrial Inflammasome Signaling and Pathogen Mimicry in Cancer Cells**. Lora Stojanovic. Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States.

A023 **Pre-clinical evaluation of the gamma-secretase inhibitor nirogacestat in an adult-type ovarian granulosa cell tumor model**. Maeva Chauvin. Massachusetts general hostpital / Harvard medical school, Boston, MA, United States.

A024 **High throughput screen for identifying inducers of Autophagic Cell Death in Ovarian Carcinoma**. Pahul Hanjra. MD Anderson Cancer Center, Houston, TX, United States.



A025 **Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer**. Paul Workman. The Institute of Cancer Research, London, London, United Kingdom.

A026 **Identifying mechanisms to target in combination with trametinib to improve therapeutic efficacy in low-grade serous ovarian cancer**. Rebekah Peplinski. University of Iowa, Iowa City, IA, United States.

A027 **Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma**. Sampsa Hautaniemi. University of Helsinki/Faculty of Medicine/ONCOSYS, Helsinki, Finland.

A028 **Investigating the role of SOX2 in promoting anchorage-independent survival of ovarian cancer cells.** Shriya Kamlapurkar. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

A029 **Development of a new iPSC-derived organoid platform to model FTE-derived HGSOC onset and progression**. Simone Roverselli. European Institute of Oncology, Milan, Italy.

A030 **Regulation of SIRT3 overexpression in Anchorage Independent Ovarian Cancer.** Sneha Srinivasan. University of Pittsburgh School of Medicine, Pittsburgh, AZ, United States.

A031 **Causal determinants of drug-resistance in patients with High-Grade Serous Ovarian Carcinoma from multi-site single cell RNA sequencing data**. Sohrab Salehi. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A032 **The role of ASIC2 and calcium influx in epithelial ovarian cancer pathogenesis**. Tanvi Joshi. USA Health Mitchell Cancer Institute, Mobile, AL, United States.

A033 **The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer**. Julia Unternaehrer. Loma Linda University, Loma Linda, CA, United States.

A034 **Combination of ATR inhibitor (ATRi) and AKT inhibitor (AKTi) reduces tumor growth and prolongs survival in BRCA2 mutant (BRCA2m) PARP inhibitor (PARPi)-resistant high-grade serous ovarian cancer (HGSC)**. Tzu-Ting Huang. National Cancer Institute, Bethesda, MD, United States.

A035 **Genome-Wide CRISPRi Screening Reveals Determinants of Platinum Sensitivity and Resistance in High-Grade Serous Ovarian Cancer**. Yi Wen Kong. David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Cambridge, MA, United States.

A036 **Nanoparticle Targeting in Platinum-Resistant Ovarian Cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance**. Yinu Wang. Northwestern University, Chicago, IL, United States.

A037 **Exploring the therapeutic effectiveness of EO3001 in the treatment of clear cell ovarian cancers with ARID1A mutations**. Yuchen Ding. The University of British Columbia, BC Cancer Research Institute, Vancouver, BC, United States.

A038 **Epigenetic compound library screen of ovarian clear cell carcinoma cell line models identifies decreased cell viability following treatment with the Bruton tyrosine kinase inhibitor ibrutinib**. Yue Ma. University of Technology Sydney, Haymarket, NSW, United States.

A039 **-SRMS confers platinum resistance in ovarian cancer through weakening MKK4-JNK-mediated apoptosis response**. Yunhan Jiang. UT Health Science Center at San Antonio, San Antonio, TX, United States.

Early Detection and Prevention

A040 **Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test**. Emily Winn-Deen. Mercy BioAnalytics Inc., Natick, MA, United States.

A041 **Low-dose aspirin use and risk of ovarian cancer: A combined analysis from two nationwide studies in Denmark and Sweden**. Guoqiao Zheng. Danish Cancer Society Research Center, Copenhagen, Denmark.

A042 **History of infertility and risk of ovarian cancer in the Women's Health Initiative**. Holly Harris. Fred Hutchinson Cancer Center, Seattle, WA, United States.

A043 **Role of stromal CD10 expression in modulating the immune microenvironment of ovarian clear cell carcinoma**. Huda Atiya. University of Pittsburgh, Pittsburgh, PA, United States.

A044 **Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer**. Jae-Hoon Kim. Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

A045 **Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model**. James Webber. Brigham and Women's Hospital, Boston, MA, United States.

A046 **Metabolomic profiles associated with breastfeeding and subsequent ovarian cancer risk**. Jennifer Mongiovi. Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital, Boston, MA, United States.



A047 **Modeling the role of the fallopian tube in the prevention and spread of high grade serous cancer using a multi-organ platform.** Joanna Burdette. University of Illinois Chicago, Chicago, IL, United States.

A048 **Utero-tubal lavage proteomic analysis: detection of ovarian cancer in BRCA mutation carriers.** Keren Levanon. Sheba Medical Center, Ramat Gan, Israel.

A049 **Fallopian tubes of BRCA carriers are characterized by an alteration of epithelial differentiation**. Quentin Chartreux. Cedars-Sinai Medical Center, Los Angeles, CA, United States.

A050 **microRNA as biomarkers in early detection and personalized treatment in ovarian cancer: Development of a personalized prevention consortium**. Renée Fortner. Cancer Registry of Norway, Oslo, Norwary.

A051 **Prior chlamydial infection and ovarian cancer risk by tumor p53 expression**. Britton Trabert. University of Utah, Salt Lake City, UT, United States.

A052 **ROS in ovulatory follicular fluid exert de novo mutagenic activities through activation-induced cytidine deaminase acting on the TP53 gene in the fallopian tube epithelial cell**. Tang-Yuan Chu. Tzu Chi Medical Center, Hualien, Taiwan.

A053 **Understanding Geospatial Relationships in Ovarian Cancer Risk**. Victoria Wang. Brigham and Women's Hospital, Boston, MA, United States.

A054 **The evolution of ovarian high grade serous carcinoma from STIC lesions**. Zhao Cheng. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Other

A056 **Development and application of an epithelial ovarian cancer-specific line of therapy algorithm using real-world data**. Connor Sweetnam. Syapse, Inc, San Francisco, CA, United States.

A057 **Inter-tumor heterogeneity revealed by multi-site whole genome sequencing of high grade serous ovarian cancer**. Elizabeth Christie. Peter MacCallum Cancer Centre, Melbourne, Australia.

A058 **Mesenchymal stem cells act as a selective pressure for High Grade Serous Ovarian Cancer initiation**. Geyon Garcia. University of Pittsburgh, Pittsburgh, PA, United States.

A059 **Stable subclones and acquired genomic events present after treatment of HGSC**. Jaana Oikkonen. University of Helsinki, Helsinki, Finland.

A060 **Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive**. Liisa Kauppi. University of Helsinki, Helsinki, Finland.



A061 **Detection and dynamic monitoring of clonal hematopoiesis mutations in women receiving systemic therapies for high grade serous ovarian carcinoma**. Rebecca Porter. Dana-Farber Cancer Institute, Boston, MA, United States.

A062 **Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in High-Grade Serous Epithelial Ovarian Cancer: the MITO-16A/MANGO-OV2A;clinical trial experience**. Sergio Marchini. HUmanitas Research Hospital, Rozzano, Italy.

Rare Ovarian Tumors

A063 **What can we learn from a retrospective evaluation of HER2, P53 and P16 INK4A protein expression in rare ovarian tumors**. Kavitha Advikolanu-Rao. TDR Services LLC., Bridgewater, NJ, United States.

A064 **Study of molecular pathways involved in the development of ovarian cancer brain metastases**. Korina Mouzakitis. Université de Sherbrooke, Sherbrooke, QC, Cananda.

A065 **High throughput drug screening to decipher the mechanisms of trametinib adaptive resistance in low-grade serous ovarian cancer cell lines**. Kwong-Kwok Wong. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A066 **The Cytotoxic effects of Oxaliplatin and 5-Fluorouracil against Low-Grade Serous Ovarian Cancer Cells**. Rewati Prakash. McGill University, Montreal, QC, Cananda.

A067 **A novel genetically engineered mouse model of ovarian carcinosarcoma**. Ruth Perets. Rambam Health Care Campus and Technion - Israel Institute of Technology, Haifa, Israel.

A068 **Dual multiplexing analysis of the tumor immune microenvironment of rare ovarian granulosa cell tumors identified predictors of recurrence and potential therapeutic targets**. Tyvette Hilliard. University of Notre Dame, South Bend, IN, United States.

Tumor Microenvironment and Immune Oncology II

A069 **High-resolution volumetric imaging of primary and metastatic high-grade serous ovarian cancer explants**. Adele Connor. University College Dublin, Dublin, Irealand.

A071 **TGF-β1/2 signaling in ovarian cancer is dependent on betaglycan ectodomain shedding that occurs in a heparan sulfate and TIMP3-dependent manner**. Alex Choi. UAB, Birmingham, AL, United States.

A072 **Altering the Ovarian Cancer Tumor Microenvironment Using CAR T Cell Therapy**. Alexandra McMellen. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A073 **Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer**. Anniina Färkkilä. University of Helsinki, Helsinki, Finland.

A074 **Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial**. Pamela Soberanis. Princess Margaret Cancer Centre, Toronto, ON, Canada.

A075 **Stromal cell DDR2 promotes ovarian cancer metastasis**. Angela Schab. Washington University in St. Louis, St. Louis, MO, United States.

A076 **T-cell exhaustion is an independent predictive biomarker of clinical outcome in high grade serous ovarian cancer regardless of homologous recombination deficiency status**. Anna Salvioni. University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France.

A077 **The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer**. Anne Knisely. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A078 **In vivo tumor micro-environment characterization: preliminary results of an ovarian cancer patients-derived co-colture organoids platform**. Floriana Camarda. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

A079 **G-CSF released from ovulation recruits and activates neutrophils in the peritoneum to aid transformation, seeding, and invasion of high-grade serous carcinoma**. Hsuan Shun Huang. Center for Prevention and Therapy of Gynecological Cancers, Department of Research, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

A080 **CD8+T-cell Interplay with Myeloid Cells as Spatial Determinant of Chemotherapy Response in the Tumor Microenvironment of Metastatic High-grade Serous Ovarian Cancer**. Inga-Maria Launonen. University of Helsinki, Helsinki, Finland.

A081 **Chromobox 2 (CBX2) drives an immunosuppressive tumor microenvironment in high grade serous carcinoma (HGSC)**. Lindsay Brubaker. University of Colorado, Denver, CO, United States.

A082 **Targeting sterol regulatory element binding protein 1 (SREBP1) improves response to standard-of-care chemotherapy;and alters the tumor microenvironment in pre-clinical models of obesity and ovarian cancer**. M. Sharon Stack. University of Notre Dame Harper Cancer Research Institute, South Bend, IN, United States.

A083 **Personalized targeted circulating tumor DNA (ctDNA) and T-cell responses after combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer**.

MacLean Sellars. Dana Farber Cancer Institute/Harvard Cancer Center, Boston, MA, United States.

A084 **AMH paracrine signaling between cancer and mesothelial cells modulates the ovarian tumor immune microenvironment.** Maeva Chauvin. Massachusetts General Hospital, Boston, MA, United States.

A085 **Evaluating the Immune Modulating Effects of Standard Chemotherapies and Macrophage-Targeted Therapy in a Humanized Patient-Derive Xenograft Model of High Grade Ovarian Cancer**. Mara Steinkamp. University of New Mexico School of Medicine, Albuquerque, NM, United States.

A086 **Rapid expansion of natural, MUC1-activated T cells from the peripheral blood of ovarian cancer patients for adoptive cell therapy**. Marion Curtis. Mayo Clinic, Scottsdale, AZ, United States.

A087 **An ovarian cancer scRNA-seq atlas to dissect tumor-host interactions underlying metastatization and chemoresistance**. Marta Sallese. European Institute of Oncology, Milan, MI, United States.

A088 **Tumor innervation as a novel driver of ovarian cancer progression**. Matthew Knarr. University of Pennsylvania, Philadelphia, PA, United States.

A089 **Influence of pre-diagnosis aspirin use on epithelial ovarian cancer tumor immune microenvironment markers: results from the Nurses' Health Study (NHS) and NHSII**. Melissa Merritt. The University of Sydney, New South Wales, Australia.

A090 **An Inflammatory Adipose Microenvironment Promotes Ovarian Cancer Tumor Growth and Cisplatin Resistance**. Michael Williams. Houston Methodist Research Institute, Houston, TX, United States.

A091 **Crosstalk between tumour vasculature and ovarian cancer stem cells: the role of L1CAM**. Micol Baronio. European Institute of Oncology IEO, Milan, MI, United States.

A092 **Ovarian Tumor Organotypic Slices Cultures for functionAl drug screening (TOSCA)**. Marianna Buttarelli. Fondazione Policlinico Universitario A.Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.

A093 **Investigating alterations in metabolic profile of ovarian carcinoma associated mesenchymal stem cells**. Roja Baruwal. University of Pittsburgh, Pittsburgh, PA, United States.

A094 **CAF-derived MFAP5 enhances immune escape through up-regulating immune checkpoint mediator CD47 in ovarian cancer cells and CD8+ T cells**. Sammy Ferri-Borgogno. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.



A095 **Long-term ovarian cancer survivors: spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface**. Sammy Ferri-Borgogno. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A096 **Blockade of LAIR1-collagen interaction enhances the therapeutic activity of BiTE-secreting T cells in ovarian cancer.** Sarah Werner. Roswell Park Comprehensive Cancer Institute, Buffalo, NY, United States.

A097 **Targeting ovarian cancer metastasis initiating cells induced by the microenvironment through ERK/EZH2/DNMT1 mediated miR-193b downregulation**. Subramanyam Dasari. Indiana University School of Medicine – Bloomington, Bloomington, IN, United States.

A098 **Microenvironment-regulated Matrix Gla Protein drives ovarian cancer stemness**. Ugo Cavallaro. European Institute of Oncology IRCSS, Milano, Italy.

A099 **Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab**. Sonali Panchabhai. Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.

A100 **Entinostat alters the M1/M2 ratio in ascites compared to tumors derived from an ID8 murine model of ovarian cancer.** Vijayalaxmi Gupta. Washington University in St. Louis, St. Louis, MO, United States.

A101 **A novel ovarian cancer organotypic tumor slice culture model**. Violaine Pourcel. Université de Sherbrooke Faculty of Medicine, Sherbrooke, QC, Cananda.

A102 **ROR2/Wnt5a signaling regulates directional cell migration and early tumor cell invasion in ovarian cancer**. Whitney Grither. Washington University, Saint Louis, MO, United States.

A103 **Improved cell phenotyping of ovarian cancer tumor microenvironment**. Ziqi Kang. Research Program in Systems Oncology, University of Helsinki, Finland, Helsinki, Finland.

Other

A104 **Normalizing the tumor microenvironment to enhance immunotherapy for ovarian cancer.** Lei Xu. Massachusetts General Hospital, Boston, MA, United States.

A105 **Untangling the effect of ascites;in shaping high grade serous ovarian cancer progression**. Pietro Lo Riso. IEO - European Institute of Oncology IRCCS, Milan, Italy.

A106 **Associations between active cytomegalovirus infection and patient-reported quality of life, fatigue and cognitive functioning among ovarian cancer survivors**. Rachel Vogel. University of Minnesota, Minneapolis, MN, United States.

A107 **Characterizing the genomic and immunologic landscape of serous borderline tumors and low-grade serous ovarian cancer**. Rahul Krishnan. University of Chicago, Chicago, IL, United States.

A108 **Aspirin and non-steroidal anti-inflammatory medication and survival following an ovarian cancer diagnosis: A Norwegian nationwide registry-based cohort study**. Renée Fortner. Cancer Registry of Norway and German Cancer Research Center, Oslo, Norway.

A109 **Novel germline genetic variants in pseudogenes associated with overall survival in advanced stage ovarian cancer treated with carboplatin, paclitaxel, and bevacizumab: Results from the ROSiA trial**. Salahaldin Alamleh. Temerty Faculty of Medicine - University of Toronto, Toronto, ON, Cananda.

A110 **Targeting Methionine Metabolism Inhibits Ovarian Cancer Stem Cells**. Shu Zhang. Indiana University Bloomington, Bloomington, IN, United States.

A111 **Development and analytical validation of a multiplexed targeted mass spectrometry assay to detect ovarian cancer protein biomarkers in sera**. Stefani Thomas. University of Minnesota, Minneapolis, MN, United States.

A112 **Mechanisms underlying platinum-induced ovarian cancer stem cell plasticity**. Tara Metcalfe. Indiana University-Bloomington, Bloomington, IN, United States.

A113 **Extracellular vesicles derived from enriched ovarian cancer stem cell fractions promote stem like properties in the more vulnerable tumor cell populations**. Venkatesh Pooladanda. Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States.

A114 **Robust Establishment and Expansion of Multilineage Human Fallopian Tube Organoids in Serum-Free Medium**. Victor Ho. STEMCELL Technologies, Vancouver, BC, Canada.

A115 **DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review**. Zoe Phan. Garvan Institute of Medical Research, Sydney, Australia.



AACR Special Conference
Ovarian Cancer
October 5-7, 2023 | Boston, MA

AACR
American Association for Cancer Research

Poster Session B (To be presented on October 6 from 7:00-9:30 p.m. ET)

Drug Discovery, Development, and Novel Pathways

B001 **Comparative exploration of cultured spheroids and organoids as models to study epithelial ovarian cancer pathobiology**. Emily Tomas. The University of Western Ontario, London, ON, Canada.

B002 **Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer**. Esther Rodman. Mayo Clinic, Rochester, MN, United States.

Epigenetics and Epitranscriptomics

B003 **A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models**. Jessica Lang. UW-Madison, Madison, WI, United States.

B004 **Precision Medicine Opportunities: uniformity across stromal components of ovarian cancer histotype contrasts heterogeneous disease.** Karolin Heinze. UBC, Vancvouver, BC, Canada.

B005 **5-Hydroxymethylcytosine profiles in serum are a predictor of chemoresistance in high-grade serous ovarian cancer**. Melanie Weigert. University of Chicago, Chicago, IL, United States.

B006 **P53 transcriptional regulation of transposable elements and the downstream immune response in ovarian cancer**. Reddick Walker. The George Washington University, Washington, DC, United States.

B007 **NAD+ metabolism drives PARPi resistance in ovarian cancer cells**. Sridevi Challa. The University of Chicago, Chicago, IL, United States.

B008 **Alternative PER2 (Period2) enhancer usage drives epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer (OC)**. Yi Chia Chiu. National Taiwan University, Taipei, Taiwan.

B009 **Dual PARP and EHMT1/2 inhibition induces an interferon response and anti-tumor immunity in ovarian cancer**. Zachary Watson. University of Colorado, Aurora, CO, United States.

Drug Discovery, Development, and Novel Pathways

B010 **Development of folate receptor alpha targeted FOXM1 inhibitors for ovarian cancer**. Adam Karpf. University of Nebraska Medical Center, Omaha, NE, United States.

B011 **GPT2 as a novel driver of platinum-resistant ovarian cancer**. Adriana Ponton-Almodovar. Michigan State University, East Lansing, MI, United States.

B012 **Transcriptomic insights reveal role of BCL2 proteins in replication checkpoint inhibitor response**. Annapoorna Venkatachalam. Mayo Clinic, Rochester, MN, United States.

B013 **Investigating Natural Killer cell therapeutic approaches for the treatment of ovarian cancer.** Aoibhin Sheedy. University of Galway, Galway, MN, United States.

B014 **Charting ovarian cancer dependencies with patient-derived organoids**. Ashley Anderson. Broad Institute, Cambridge, MA, United States.

B015 **CCDC80 as a novel cell intrinsic tumor suppressor protein in high grade serous ovarian cancer**. Aya Saleh. Technion-Israel Institute of Technology and Rambam Health Care Campus, Haifa, Israel.

B016 **Repurposing nelfinavir for re-sensitizing platinum-resistant high grade serous ovarian cancer cells**. Benjamin Forgie. Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, QC, Canada.

B017 **Understanding the impact of transporter heterogeneity on the efficacy of PARP inhibitors**. Carmen Ramirez Moncayo. Medical Research Council London Institute of Medical Sciences, London, United Kingdom.

B018 **Enhanced transfection efficiency with folic acid conjugated synthetic polymer nanoparticles for high grade serous ovarian cancer**. Chaebin Lee. Brigham and Women's hospital, Boston, MA, United States.

B019 **Investigating Cannabis sativa bioactive compounds as an anti-cancer treatment in high-grade serous ovarian cancer**. Claire Hughes. University College Dublin, Dublin, Ireland.

B020 **M1 macrophage engineered vesicles as ovarian cancer treatment in a mouse xenograft model**. Connie Cao. University of Kentucky, Lexington, KY, United States.

B021 **A phase 1 dose escalation study of lapatinib and paclitaxel in recurrent ovarian cancer.** Connie Cao. University of Kentucky, Lexington, KY, United States.

B022 **Treatment stratification of targeted therapy in patients with recurrent ovarian cancer by signal transduction pathway activity profiling: the prospective STAPOVER study.** Cynthia Hendrikse. Catharina Hospital Eindhoven, Eindhoven, Neverland.

B023 **Modeling of New Drugs Clinical Trials Outcome with Patients' Digital Twins Cohorts**. Dmitrii Chebanov. BioAlg, Covina, CA, United States.

B024 **Maintenance therapy inhibition of ptk2 yields decreased disease in preclinical HRP/HRD models of recurrent HGSOC**. Dwayne Stupack. University of California, San Diego Moores Cancer Center, La Jolla, CA, United States.

B025 **Hypoxia inducible factor 1 alpha regulates tumor progression in a human epithelial ovarian cancer model**. María José España De Marco. Instituto de Biologia y Medicina Experimental - CONICET, Ciudad Autónoma de Buenos Aires, Argentina.

B026 **RPL8 amplification in high grade serous ovarian cancer is a frequent event and is correlated to outcome and response to treatment**. Marianna Penzo. University of Bologna, Bologna, Italy.

B027 **Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment**. Marie Bay. Danish Cancer Institute, Copenhagen, Denmark.

B028 **Unraveling the Role of Matrix Metalloproteinase 3 (MMP3) in Cisplatin Resistance of Ovarian Cancer**. Mariela Rivera-Serrano. University of Puerto Rico Rio Piedras Campus, San Juan, Puerto Rico.

B029 **Targeting non-canonical function of TXNRD1 to overcome platinum resistance by eradicating ovarian cancer stem-like cells**. Martina Towers. MD Anderson, Houston, TX, United States.

B030 **PARP-1 inhibition results in ovarian and endometrial cancer cell death by disrupting the nucleolar localization of the RNA helicase DDX21 which is associated with decreased survival outcomes**. Marwa Aljardali. UT Southwestern Medical Center, Dallas, TX, United States.

B031 **The PLK1 inhibitor Volasertib as a treatment for HSF1 and MYC coamplified ovarian cancer**. Matthew O'Malley. Indiana University School of Medicine, Bloomington, IN, United States.

B032 **Probing the molecular crosstalk between ovarian cancer and omentum**. Monica Haughan. University of Illinois at Chicago, Chicago, IL, United States.

B033 **Evaluating the Impact of Vascular Endothelial Growth Factor Targeted Treatment on Survival Outcomes and Adverse Events in Ovarian Cancer: an Updated Systematic Review and Meta-analysis**. Muhammed Elfaituri. University of Tripoli, Tripoli, Lebanon.

B034 **Targeting the HER family/Src pathways in ovarian cancer**. Neil Conlon. Dublin City University, Dublin, Ireland.

B035 **Cyclin E1 Positive Staining Is Frequent and Independent of Prior Platinum Treatment in High Grade Serous Ovarian Cancer**. Olivier Harismendy. Zentalis Pharmaceuticals, San Diego, CA, United States.

Early Detection and Prevention

B036 **Spatial transcriptomics reveals stepwise biomolecular changes in ovarian cancer tumor microenvironments**. AASA SHIMIZU. The University of Chicago, Chicago, IL, United States.

B037 **Physical inactivity is associated with ovarian cancer in women of African ancestry**. Albina Minlikeeva. University at Buffalo, Buffalo, NY, United States.

B038 **Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells**. Amrita Salvi. University of Illinois, Chicago, Chicago, IL, United States.

B039 **Identification of ovarian cancer protein biomarkers in liquid-based Pap tests**. Amy Skubitz. University of Minnesota, Minneapolis, MN, United States.

B040 **OvaPrintTM – a novel cfDNA methylation liquid biopsy for cancer risk assessment in epithelial ovarian cancer**. David Buckley. University of Southern California, Los Angeles, CA, United States.

B041 **Modeling the malignant transformation of fallopian tube epithelium driven by extracellular vesicles cargos in an organ-on-chip microphysiological system**. Didi Zha. University of Illinois at Chicago, CHICAGO, IL, United States.

B042 **Feasibility of an Electronic Medical Records Based Ovarian Cancer Symptom Screening Patient Questionnaire**. Kian Behbakht. The University of Colorado, Aurora, CO, United States.

B043 **Feasibility of a traceback approach to facilitate genetic testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) study**. Larissa White. Kaiser Permanente Colorado Institute for Health Research, Aurora, CO, United States.

B044 **Serum miRNA expression in ovarian cancer patients is independent of histological subtype and FIGO stage**. Laura Wollborn. Brigham and Women's Hospital, Boston, MA, United States.

B045 **In vivo ovarian cancer detection using folate receptor-α targeted iron oxide nanoparticles**. Marie Zhang. Imagion Biosystems, Inc., San Diego, CA, United States.

B046 **Lack of ER/PR expression and unresponsiveness to oral contraceptives in fallopian tube stem/progenitor cell states: Reevaluating the mechanism of cancer prevention**. Megan Ritting. Mayo Clinic, Rochester, MN, United States.

B047 **Development and validation of an improved risk stratification model for ovarian cancer**. Minh Tung Phung. University of Michigan School of Public Health, Ann Arbor, MI, United States.

B048 **Evaluating the impact of pulmonary diseases on the use of microRNAs as biomarkers for early detection of ovarian cancer**. Monica Moore. Howard University, Washington, DC, United States.

B049 **Assessing the Utility and Accuracy of the Copenhagen Index in Ovarian Cancer Triage: Evidence From a Meta-analysis**. Muhammed Elfaituri. University of Tripoli, Tripoli, Lebanon.

B050 **Evaluation of the Predictive Power of the Assessment of Different NEoplasias in the adneXa (ADNEX) Model for Preoperative Ovarian Cancer Risk in Adnexal Masses: A Diagnostic Accuracy Meta-analysis**. Muhammed Elfaituri. University of Tripoli, Tripoli, Lebanon.

B051 **Genome-wide association studies of 26,187 women without ovarian cancer identifies 12 genetic loci of blood CA125**. Naoko Sasamoto. Brigham and Women's Hsopital, Boston, MA, United States.

B052 **Ovarian cancer risk prediction: A systematic assessment of the state of the art and development of a new model**. Nicolas Wentzensen. National Cancer Institute, Rockville, MD, United States.

Rare Ovarian Tumors

B053 **Lipid metabolism and lipidomics of ovarian clear cell carcinoma: A comprehensive analysis**. Agnes Bilecz. University of Chicago, Chicago, IL, United States.

B054 **Defective STING Signaling in Low-Grade Serous Ovarian Cancer: An Opportunity for Oncolytic Viruses Therapy**. Dawn Cochrane. British Columbia Cancer Research Centre, Vancouver, BC, United States.

B055 **Identifying compounds to promote apoptotic cell death in clear cell ovarian cancer**. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

B056 **The Unconfounded Effect of Bevacizumab on Advanced Ovarian Clear Cell Carcinoma: A Systematic Review, Traditional Meta-Analysis, and Network Meta-Analysis**. Fisher Huang. National Taiwan University Hospital, Yunlin Branch, Yunlin county, Taiwan.

B057 **Oncogenic Foxl2 directs enhancer reprogramming and changes in 3D genome structure in ovarian granulosa cell tumors**. Veena K. Vuttaradhi. University of Texas MD Anderson Cancer Center, HOUSTON, TX, United States.

B058 **Targeting Mediator Kinase CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma.** Wade Barton. The University of Alabama, Birmingham, AL, United States.

B059 **A patient-derived xenograft (PDX) orthotopic mouse model of rare gynecologic mesonephric-like adenocarcinoma as a platform of personalized medicine.** Yasuto Kinose. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Tumor Microenvironment and Immune Oncology II

B060 **Spatial landscape of cell cycle dynamics post-neoadjuvant chemotherapy in high-grade serous ovarian carcinoma**. Ada Junquera. University of Helsinki, Helsinki, Finland.

B061 **Multiparametric;single-cell characterization of the immune tumor microenvironment of HGSC tumors before and after neoadjuvant chemotherapy**. Antonio Delgado-Gonzalez. Stanford University, Stanford, CA, United States.

B062 **Role of cancer associated fibroblasts in ovarian cancer relapse**. Argha Ghosh. Indiana University School of Medicine - Bloomington, Bloomington, IN, United States.

B063 **Vascular senescence associated cell migration inducing hyaluronidase-1 production promotes ovarian cancer migration and tumorigenesis**. Asha Kumari. Department of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

B064 **Reconstructing the metastatic tumour microenvironment of high grade serous ovarian cancer using human;multicellular in vitro models**. Beatrice Malacrida. Queen Mary University of London, London, United Kingdom.

B065 **Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment**. Benjamin Bitler. The University of Colorado, Denver, CO, United States.

B066 **Elucidating the impact of ascites on high grade serous ovarian cancer through in vitro multi-model characterization**. Bianca Barzaghi. European Institute of Oncology, Milan, MI, United States.

B067 **Omentin: A novel immune modulator in the pro-inflammatory omental microenvironment of high-grade serous ovarian cancer**. Chi Lam Au Yeung. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B068 **FOXM1 mediates the crosstalk between tumor microenvironment and ovarian cancer stem cells as revealed by patient-derived organotypic models**. Chiara Battistini. European Institute of Oncology IRCCS, Milan, Italy.

B069 **Bone marrow-derived adipocytes promote ovarian cancer progression and metastasis**. Courtney Bailey. University of Colorado, Aurora, CO, United States.

B070 **Logic-gated CAR T cell product AB-1015 response to ovarian cancer models with heterogeneous levels of ALPG/P antigen**. Dina Polyak. ArsenalBio, South San Francisco, CA, United States.

B071 **Mesothelial cell motility and contractility promote ovarian cancer metastatic potential through a PKA-dependent mechanism**. Dorota Jazwinska. University of Pittsburgh, Pittsburgh, PA, United States.

B072 **Claudin-4 modulates autophagy via cell-cell junctions as a cellular protective mechanism before genomic instability in ovarian cancer.** Fabian Villagomez. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B073 **A spatially resolved single-cell tumor microenvironment of clinicomolecular subtypes of high-grade serous ovarian cancer**. Fernando Perez-Villatoro. University of Helsinki, Faculty of Medicine, Research program in systems oncology., Helsinki, Finland.

B074 **Proteogenomic Analysis of Enriched Tumor Epithelium Identifies Prognostic Signatures and an Increased Dependency of Homologous Recombination Proficient Cells on BMI1 in High Grade Serous Ovarian Cancer**. Thomas Conrads. Inova Health System, Falls Church, VA, United States.

B075 **Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity**. Gurkan Mollaoglu. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

B076 **Targeting Cancer Glycomes Sensitizes Ovarian Tumors to Immunotherapy**. Hao Nie. MD Anderson Cancer Center, Houston, TX, United States.

B077 **Spatial patterns of immune cell states are associated with poor response to neoadjuvant chemotherapy in high-grade serous ovarian cancer**. Iga Niemiec. University of Helsinki, Helsinki, Finland.

B078 **Insulin-like growth factor signaling contributes to omental preadipocyte-mediated tumorigenesis in ovarian cancer by regulating expression of extracellular matrix genes**. Jennifer Waters. San Diego State University, San Diego, CA, United States.

B079 **Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR-T cell activity**. Joash Joy. Queen Mary University of London, London, United States.

B080 **AB-1015, an Integrated Circuit T (ICT) cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer**. Jun Feng. Arsenal Biosciences, Inc., San Francisco, CA, United States.

B081 **Type-I interferon (IFN-I) signaling following aurora kinase A (AURKA) inhibition is modulated by tumor p53 status**. Karen McLean. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

B082 **A pro-tumorigenic, aged microenvironment may aid in worsened disease progression in an HGSOC model**. Katherine Cummins. University of Pennsylvania, Philadelphia, PA, United States.

B083 **Single-cell and spatial transcriptomic characterization of treatment resistance and immune dynamics in high-grade serous ovarian cancer**. Kathleen Imbach. Josep Carreras Leukemia Research Institute, Barcelona, Spain.

B084 **Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer**. Kristin Anderson. University of Virginia, Charlottesville, VA, United States.

B085 **Carcinoma-associated mesenchymal stem cells promote high-grade serous ovarian cancer metastasis and drive tumor heterogeneity at the metastatic site through direct mitochondrial transfer**. Leonard Frisbie. University of Pittsburgh, Pittsburgh, PA, United States.

B086 **Novel myeloid activation therapy promotes regression of metastatic ovarian cancer**. Nan Zhang. The Wistar Institute, Philadelphia, PA, United States.

B087 **Targeting myeloid derived suppressor cell migration decreases tumor progression in a murine model of ovarian cancer**. Nicole Marjon. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B088 **Elucidating the role of amphiregulin in the ovarian tumor immune microenvironment**. Nicole James. Women and Infants Hospital of Rhode Island/ Warren Alpert Medical School of Brown University, Providence, RI, United States.

B089 **Intratumoral expression analysis of mast cells in high grade serous ovarian cancer**. Nicole James. Women and Infants Hospital of Rhode Island / Warren Alpert Medical School of Brown University, Providence, RI, United States.

B090 **Gut microbial suppression of Epithelial Ovarian Cancer and attenuation of chemoresistance. Opportunity for probiotics in patient care to improve survival.** Ofer Reizes. Cleveland Clinic, Cleveland, OH, United States.

B091 **Mechanisms underlying the omental support of ovarian cancer peritoneal metastasis**. Rachel Mintz. Washington University in St. Louis, St.Louis, MO, United States.

Other

B092 **Development of Predictive Models for expression of a tumor specific biomarker and CD3 on H&E Digital Slides**. Alan Jerusalmi. Bio-AI Health, Goffstown, NH, United States.

B093 **Investigating early events of ovarian cancer transcoelomic metastasis identifies the small Rho-GTPase RHOV as an essential gene for cellular detachment and aggregate formation**. Amal Elhaw. University of Pittsburgh, Pittsburgh, PA, United States.

B094 **A combined RAD51 and phosphorylated replication protein assay predict response to platinum chemotherapy in high-grade serous ovarian cancer**. Mary Mullen. Washington University in St Louis, St Louis, MO, United States.

B095 **Tenascin C promotes ovarian cancer stem cells interactions with the niche**. Amber Rogers. Indiana University School of Medicine, Indianapolis, IN, United States.

B096 **Targeting RNA splicing factor RBM39 improves therapy responses in ovarian high-grade serous carcinoma**. Anke Nijhuis. Imperial College London, London, United Kingdom.

B097 **Image analysis-guided spatial transcriptomics improves recognition of biological features important for outcome in high grade serous carcinoma**. Anna Laury. University of Helsinki, Helsinki, Finland.

B098 **Impact of dexamethasone on chemotherapy response in ovarian cancer**. Annapoorna Venkatachalam. Mayo Clinic, Rochester, MN, United States.

B099 **A Common WNT4 Polymorphism Drives Gynecologic Cancer Phenotypes and Health Disparities**. Benjamin Bitler. The University of Colorado, Denver, CO, United States.

B100 **Perfluoroalkyl substances (PFAS) induce platinum resistance in ovarian cancer through altering mitochondrial function**. Brittany Rickard. University of North Carolina, Chapel Hill, NC, United States.

B101 **Characterizing somatic TP53 mutations in non-cancerous and high-risk fallopian tubes using ultra-deep sequencing**. CoohleenAnn Coombes. University of Washington, Seattle, WA, United States.

B102 **Mutational and copy number-based ctDNA profiles mirror High-Grade Serous Cancer tumors and enable detection of genetic changes appearing at recurrence**. Giovanni Marchi. University of Helsinki, Helsinki, Finland.

B103 **The impact of ULK1 deficiency on autophagy, cell viability, and tumour progression in experimental models of ovarian cancer metastasis**. Jack Webb. Western University, London, ON, United Kingdom.



B104 **Establishing patient derived organoids for high-grade serous ovarian cancer as representative models for pre-clinical research**. James Clark. Imperial College London, London, United Kingdom.

B105 **Long-term episodic APOBEC3A activity promotes metastatic ovarian cancer progression**. Jessica Devenport. Washington University in Saint Louis, Saint Louis, MO, United States.

B106 **A minimal driver pair for a spontaneous high-grade serous ovarian cancer mouse model: Myc and p53-R270H**. Joe Delaney. Medical University of South Carolina, Charleston, SC, United States.

B107 **Elucidating the Influence of Long-Chain Fatty Acids on Ovarian Cancer Progression**. Jumpei Ogura. Kyoto University, Kyoto, Japan.

B108 **Zinc finger protein 217 (ZNF217) promotes ovarian cancer metastasis through interaction with estrogen**. Kathryn Wardrup. University of Maryland Baltimore County, Baltimore, MD, United States.

B109 **Uncovering novel vulnerabilities in ovarian cancer by studying cell death in neoplastic transformation**. Lissah Johnson. John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, United States.

B110 **Bridging the academic-industry gap to promote health equity: RE-AIMing the implementation of the AKRIVIS GDTM test go-to-market strategy**. Margo Harrison. AOADx, Boulder, CO, United States.

B111 **Mechanism-informed photochemical strategies to overcome fluid shear stress-induced platinum resistance in ovarian cancer**. Marta Overchuk. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

B112 **A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors**. Charles Lin. Kronos Bio, Cambridge, MA, United States

B113 **Associations between risk factors and epithelial ovarian cancer survival by racial and ethnic group: an analysis from the Ovarian Cancer Association Consortium.** Nicola Meagher. The Daffodil Centre, Sydney, NSW, Australia.

B114 **Effect of spatial and temporal Inter-tumoral heterogeneity on Homologous Recombination Deficiency scores in High Grade Serous Ovarian Cancer**. Paula Cunnea. Imperial College London, London, United Kingdom.